MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (OP:BVAXF)

0.0446 UNCHANGED
Streaming Delayed Price Updated: 3:48 PM EDT, Apr 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0446
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0446
Today's Range 0.0446 - 0.0446
52wk Range 0.0148 - 0.2210
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
VANCOUVER, BC, April 28 2026 - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the... 
Via TheNewswire.com
BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
VANCOUVER, BC, April 27th, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0) today announced the acceptance of an abstract related to the PESCO study, an... 
Via TheNewswire.com

Performance

YTD
-74.0%
-74.0%
1 Month
-23.0%
-23.0%
3 Month
-71.6%
-71.6%
6 Month
-73.7%
-73.7%
1 Year
+67.7%
+67.7%

More News

Read More
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Via TheNewswire.com
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Via TheNewswire.com
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
Via TheNewswire.com
News headline image
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
Via TheNewswire.com
Topics Artificial Intelligence
News headline image
BioVaxys Announces Application for Management Cease Trade Order
Via TheNewswire.com
News headline image
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
Via TheNewswire.com
News headline image
BioVaxys 1Q2026 R&D and Collaborative Activity
Via TheNewswire.com
News headline image
2025 Corporate Review
Via TheNewswire.com
News headline image
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Via Newsfile
News headline image
BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
Via TheNewswire.com
Topics Intellectual Property
InvestorNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement
Via Investor Brand Network
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
From Virtual Investor Conferences
Via GlobeNewswire
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
Via FinancialNewsMedia
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Via FinancialNewsMedia
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
Via FinancialNewsMedia
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Via FinancialNewsMedia
Topics Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
Via FinancialNewsMedia
News headline image
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
Via FinancialNewsMedia
Topics Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
Via FinancialNewsMedia
Topics Economy
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
Via FinancialNewsMedia

Frequently Asked Questions

Is Biovaxys Technology Corp publicly traded?
Yes, Biovaxys Technology Corp is publicly traded.
What exchange does Biovaxys Technology Corp trade on?
Biovaxys Technology Corp trades on the OTC Traded
What is the ticker symbol for Biovaxys Technology Corp?
The ticker symbol for Biovaxys Technology Corp is BVAXF on the OTC Traded
What is the current price of Biovaxys Technology Corp?
The current price of Biovaxys Technology Corp is 0.0446
When was Biovaxys Technology Corp last traded?
The last trade of Biovaxys Technology Corp was at 04/29/26 03:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story